Valuation: Lucy Scientific Discovery Inc.

Market Cap 907K 806K 752K 685K 1.29M 87.18M 1.3M 9.1M 3.53M 44.57M 3.4M 3.33M 143M P/E 2022 *
-
P/E 2023 -1.63x
Enterprise Value 1.02M 908K 847K 772K 1.46M 98.23M 1.47M 10.25M 3.97M 50.22M 3.84M 3.75M 161M EV / Sales 2022 *
-
EV / Sales 2023 2,682,682,605x
Free-Float
81.97%
Yield 2022 *
-
Yield 2023 -
6 months-50.00%
Current year-66.67%
Current year 0
Extreme 1.0E-5
0
1 year 0
Extreme 1.0E-5
0.01
3 years 0
Extreme 1.0E-6
4.6
5 years 0
Extreme 1.0E-6
40
10 years 0
Extreme 1.0E-6
40
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 75 2021-01-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/13/23 Others

Chief Technology Officer

85,000 -
2/13/23 Others

Chief Executive Officer

984,590 -
2/13/23 Others

Director

9,309 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-50.00%-100.00% 176
-0.61%-3.43%+36.07%+117.61% 1,019B
-1.02%-5.60%+35.72%+64.82% 617B
+1.11%-0.58%+12.36%+78.27% 464B
+0.34%-3.01%+61.79%+41.79% 356B
-0.95%-4.05%+20.54%+40.33% 333B
-1.46%-2.89%+10.57%+26.54% 267B
-1.35%-5.43%-6.17%+8.82% 244B
-1.04%-2.79%+35.30%+54.42% 218B
-1.87%-4.10%+28.44%+97.54% 179B
Average -0.68%-3.05%+18.46%+43.01% 369.72B
Weighted average by Cap. -0.60%-3.33%+29.07%+71.15%

Financials

2022 2023
Net sales - 0.01 0.01 0.01 0.01 0.01 0.68 0.01 0.07 0.03 0.35 0.03 0.03 1.11
Net income -5.86M -5.2M -4.86M -4.43M -8.35M -563M -8.43M -58.77M -22.77M -288M -21.99M -21.51M -924M -8.99M -7.99M -7.45M -6.79M -12.81M -864M -12.93M -90.2M -34.95M -442M -33.75M -33.01M -1.42B
Net Debt 4.77M 4.23M 3.95M 3.6M 6.79M 458M 6.86M 47.83M 18.53M 234M 17.89M 17.51M 752M 115K 102K 95.3K 86.87K 164K 11.05M 165K 1.15M 447K 5.65M 431K 422K 18.13M
Logo Lucy Scientific Discovery Inc.
Lucy Scientific Discovery Inc. is an early stage psychotropics contract manufacturing company. The Company is engaged in researching, developing, and manufacturing psychotropic drugs. The Company is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. It is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The Company is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.
Employees
-
Date Price Change Volume

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LSDI.F Stock